MD

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Retrieved on: 
수요일, 3월 13, 2024

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Key Points: 
  • Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
  • The article summarizes the procedure and the follow up at 6 months, which showed continued good prosthetic performance.
  • Examination through a transesophageal echocardiogram revealed excellent valve performance, with neither mitral regurgitation nor paravalvular leak.
  • Mitral valve regurgitation is a serious and potentially fatal disease affecting 2% of the world's population, or approximately 160 million people.

EQS-News: Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Retrieved on: 
수요일, 3월 13, 2024

“Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

Key Points: 
  • “Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • We believe that the data set provides biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Recent third-party data in post COVID patients identified EBV reactivation as a potential cause for fatigue in this patient group.
  • Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Retrieved on: 
수요일, 3월 13, 2024

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Key Points: 
  • Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
  • This first implantation of the artificial urinary sphincter Artus was successfully performed by Prof. Roman Zachoval, MD, PhD, head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic, on a 68-year-old male with severe urinary incontinence.
  • “Artus is easy to prepare and implant due to its innovative design compared to the previous generation of urinary sphincters.
  • Artus is an implantable artificial urinary sphincter developed for the treatment of moderate to severe urinary incontinence in both men and women.

Terminus Group Inaugurates International Headquarters in UAE

Retrieved on: 
목요일, 3월 7, 2024

Abdulla Al Saleh, the Under Secretary of the Foreign Trade and Industry at the UAE Ministry of Economy, Victor AI, Founder and CEO of Terminus Group, Dr. Ling Shao, President of Terminus International and Chief Scientist of Terminus Group, and representatives from ecological cooperators attended the opening ceremony.

Key Points: 
  • Abdulla Al Saleh, the Under Secretary of the Foreign Trade and Industry at the UAE Ministry of Economy, Victor AI, Founder and CEO of Terminus Group, Dr. Ling Shao, President of Terminus International and Chief Scientist of Terminus Group, and representatives from ecological cooperators attended the opening ceremony.
  • Victor AI, Founder and CEO of Terminus Group (R3), Dr. Ling Shao, President of Terminus International and Chief Scientist of Terminus Group (L3), Kevin Shi, CFO of Terminus Group (R2), Eric Wan, VP of Alibaba Cloud Intelligence International, GM of Alibaba Cloud Middle East and Africa Region (L2), Pouya Parsafar, CEO of Enterprise Systems (L1), and Wang Yizhou, MD of China Mobile International Middle East & Africa region (R1) jointly kicked off the inauguration of Terminus International Headquarters
    H.E.
  • We expect the continued success of Terminus Group, one of the world's leading technology companies, and hope Terminus International Headquarters will continue to support and deeply engage in the green and digital future cities development in UAE.
  • Victor AI, Founder and CEO of Terminus Group, is in Terminus International Headquarters

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
수요일, 3월 6, 2024

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

Elsevier Health Launches ClinicalKey AI, the Most Advanced Gen AI-Powered Clinical Decision Support Tool for Clinicians

Retrieved on: 
목요일, 2월 29, 2024

New York, New York--(Newsfile Corp. - February 29, 2024) - Elsevier Health, a global leader in medical information and data analytics, today launched ClinicalKey AI, the first and most advanced clinical decision support tool to be introduced in the US that combines the latest and most trusted medical content with generative artificial intelligence (AI) to help clinicians at the point of care. ClinicalKey AI has been launched in partnership with OpenEvidence, a company specializing in AI for medicine.

Key Points: 
  • ClinicalKey AI has been launched in partnership with OpenEvidence, a company specializing in AI for medicine.
  • Our work with Elsevier Health has allowed us to deliver a superior user experience, combining trusted medical content with advanced AI technology through ClinicalKey AI.
  • ClinicalKey AI is built and maintained to deliver the accuracy and relevance of insights that healthcare institutions and physicians expect from Elsevier Health.
  • Attendees at the upcoming HIMSS Conference (March 11-15) can experience an in-person demonstration of ClinicalKey AI by visiting Elsevier at Booth 3048.

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

Retrieved on: 
월요일, 3월 11, 2024

FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).

Key Points: 
  • FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).
  • “CML is a serious leukemia that requires chronic, life-long treatment,” said Emil Kuriakose, MD, chief medical officer of Terns.
  • Orphan drug designation for TERN-701 underscores the FDA’s recognition of the unmet need for people living with CML and Terns’ commitment to developing new treatment options.”
    FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States.
  • Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity.

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
월요일, 3월 11, 2024

“Bringing together our dedicated, world-class team of acknowledged strategic and clinical experts has enabled us to position Ocular as a leader in retinal care.

Key Points: 
  • “Bringing together our dedicated, world-class team of acknowledged strategic and clinical experts has enabled us to position Ocular as a leader in retinal care.
  • Total net revenue was $14.8 million for the fourth quarter of 2023, a 5.0% increase over total net revenue of $14.1 million in the comparable period in 2022, driven by DEXTENZA sales.
  • General and administrative expenses were $8.0 million for the fourth quarter of 2023 versus $8.3 million in the comparable quarter of 2022, lower primarily due to a reduction of professional-related fees and other expenses.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $5.3 million in the fourth quarter of 2023 versus $4.7 million for the comparable quarter in 2022.

America’s Blood Centers Recognizes Exceptional Contributions to Blood Donation and Strengthening the Blood Supply

Retrieved on: 
월요일, 3월 11, 2024

This award recognizes an ABC partner for their commitment to saving lives, helping communities, and supporting the blood supply.

Key Points: 
  • This award recognizes an ABC partner for their commitment to saving lives, helping communities, and supporting the blood supply.
  • ABC and HOSA announced a multi-year national partnership in 2022 to encourage blood donation and careers at community blood centers.
  • Blood Centers of California is a collaborative network comprised of 11 non-profit blood centers across the state that ensure a safe and available blood supply for California's healthcare facilities, physicians, and patients.
  • Founded in 1962, America’s Blood Centers is the national organization bringing together community-based, independent blood centers.

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Retrieved on: 
월요일, 3월 11, 2024

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.
  • This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.
  • Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F.
  • This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.”